This roundtable series delves into therapies used for limited-stage small cell lung cancer or early-stage non–small cell lung cancer, as discussed by participants at virtual live events.
Part 2: Considerations for Using Adjuvant Chemotherapy and Osimertinib in NSCLCJune 13th 2022
During a live virtual event, Aaron E. Lisberg, MD, discussed the use of adjuvant chemotherapy regimens and the significance of the ADAURA trial of osimertinib for patients with early-stage non–small cell lung cancer with certain EGFR mutations.
The Importance of Molecular Testing Before Adjuvant Therapy for NSCLCJanuary 24th 2023
During a Targeted Oncology case-based roundtable event, Edward S. Kim, MD, MBA, discussed adjuvant therapy options and the use of molecular testing in patients with earlier-stage non–small cell lung cancer. This is the first of 2 articles based on this event.
Chemotherapy’s Role Reevaluated in Early-Stage EGFR+ NSCLCFebruary 10th 2023
During a Targeted Oncology™ Case-Based Roundtable™ event, Edward S. Kim, MD, MBA, discussed the use of adjuvant therapies including chemotherapy and osimertinib in patients with non–small cell lung cancer.